ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need
Proceeds to support continued clinical advancement of lead program, VGA039, a first-in-class antibody targeting protein S for the treatment of bleeding disorders, starting with von Willebrand disease (VWD)
ROC-101 exhibits favorable pharmacokinetics for once-daily dosing
Funding to advance first-in-class pan-ROCK inhibitor through Phase 2a testing in PAH and ILD-PH patients
Warner Biddle describes the trajectory of the field, and how neuro-autoimmune conditions have emerged as Kyverna’s most advanced programs. We discuss Stiff Person Syndrome, myasthenia gravis, MS and more.
NEULARK trial to evaluate NEU-411, a brain-penetrant, potent and selective LRRK2 inhibitor, in people with LRRK2-driven Parkinson’s disease; topline data anticipated in 2027
Capsida is initiating the Phase 1/2 study for CAP-003, with the first patient expected to be dosed in the third quarter of this year
Capsida will also present data from its potential best-in-class programs for Parkinson’s disease associated with GBA mutations (CAP-003 PD-GBA) and Friedreich’s ataxia (CAP-004), as well as capsid engineering and manufacturing
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration support advancing CAP-003 into clinical development in 1H25.
Neuron23 today announced the publication of a manuscript in the Proceedings of the National Academy of Sciences (PNAS), which explores the role of tyrosine kinase 2 (TYK2) inhibition in neuroinflammation, microglia and astrocyte regulation, and modulation of various biomarkers of neuroinflammation in Experimental Autoimmune Encephalomyelitis (EAE), a widely utilized model of multiple sclerosis (MS) and neuroinflammation.
